UPDATE: Ascendiant Capital Markets Reiterates On Repros Therapeutics Following Positive Topline Results
In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX), and raised the price target from $23.00 to $25.00.
In the report, Ascendiant Capital Markets noted, “We believe that the positive result from the ZA-305 study bodes well for a positive result from the ZA-304 study, given that the trials are identical in design. Further, we believe that positive results from these studies will also be valuable in supporting potential labeling claims for superiority of Androxal over Androgel, which would improve the commercial attractiveness of the product. Our 12 month PT is calculated using an NPV analysis.”
Repros Therapeutics closed on Thursday at $18.21.
Latest Ratings for RPRX
|Nov 2016||Ladenburg Thalmann||Upgrades||Neutral||Buy|
|Dec 2015||Brean Capital||Terminates||Buy|
|Oct 2015||Brean Capital||Downgrades||Buy||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.